Edgar Filing: JORDAN GREGORY D - Form 4

JORDAN GRE	GORY D										
Form 4											
February 02, 20											
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISS						COMMISSION		PROVAL 3235-0287			
Check this b if no longer subject to Section 16. Form 4 or Form 5 obligations may continu <i>See</i> Instructi 1(b).	STATI Filed p e. Section 1	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section							Expires:January 312005Estimated averageburden hours perresponse0.5		
(Print or Type Res	ponses)										
JORDAN GREGORY D Sym KIN			Symbol	ING PHARMACEUTICALS INC				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O KING PH INC., 501 FIF			3. Date of (Month/D 01/31/20	-	ansaction			X Director Officer (give below)		o Owner er (specify	
	(Street)	(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 					
BRISTOL, TN	37620							Person	More than One Re	porting	
(City)	(State)	(Zip)	Table	e I - Non-D	erivative S	ecurit	ies Acq	uired, Disposed o	f, or Beneficial	ly Owned	
	. Transaction I Month/Day/Ye	ar) Executionany	on Date, if	3. Transactic Code (Instr. 8) Code V	on(A) or Dis (D)	sposed	of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock 0	1/31/2011			U	41,679	D	<u>(1)</u>	0	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration I (Month/Day	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Restricted Stock Units	(2)	01/31/2011		D	16,201	(3)	<u>(4)</u>	Common Stock	16,201	
Stock Option (Right to Buy)	\$ 14	01/31/2011		J	10,000	(5)	08/04/2013	Common Stock	10,000	
Stock Option (Right to Buy)	\$ 8	01/31/2011		J	10,000	(5)	04/29/2015	Common Stock	10,000	

Reporting Owners

Reporting Owner Name	Relationships					
			10% Owner	Officer	Other	
JORDAN GREGORY D C/O KING PHARMACEU' 501 FIFTH STREET BRISTOL, TN 37620	TICALS, INC.	Х				
Signatures						
/s/ Gregory D. Jordan	02/02/2011					
<u>**</u> Signature of	Date					

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The reported transaction represents shares of common stock tendered to Parker Tennessee Corp. ("Acquisition Sub"), a wholly-owned subsidiary of Pfizer Inc. ("Pfizer"), pursuant to Acquisition Sub's offer to purchase all of the issued and outstanding shares of common

- (1) stock, no par value per share, of King Pharmaceuticals, Inc. ("King") at a price of \$14.25 per share, net to the seller in cash, without interest and less any required withholding taxes, upon the terms and conditions described in the Tender Offer Statement on Schedule TO filed with the SEC by Pfizer and Acquisition Sub on October 22, 2010, as amended (the "Tender Offer").
- (2) Each Restricted Stock Unit ("RSU") represents a right to receive one share of common stock of King.

Reporting Person

Edgar Filing: JORDAN GREGORY D - Form 4

Edgar Filing: JORDAN GREGORY D - Form 4

Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2010, among Pfizer, King and Acquisition Sub (the "Merger Agreement"), these RSUs, whether or not vested, were fully vested immediately prior to and canceled immediately following Acquisition

(3) Sub's acceptance of the common stock tendered and not validly withdrawn in accordance with the Tender Offer Statement on Schedule TO filed with the SEC by Pfizer and Acquisition Sub on October 22, 2010, as amended (the "Acceptance Time") in exchange for the right to receive cash payment for each RSU of \$14.25, net to the seller in cash, without interest and less any required withholding taxes.

Pursuant to the Merger Agreement, these RSUs, whether or not vested, were fully vested immediately prior to and canceled immediately(4) following the Acceptance Time in exchange for the right to receive cash payment for each such RSU of \$14.25, net to the seller in cash, without interest and less any required withholding taxes.

Pursuant to the Merger Agreement, these stock options, whether or not vested, were fully vested immediately prior to and canceled immediately following the Acceptance Time in exchange for the right to receive cash payment for each such option of the excess of

(5) Infinite fractional of the fractional of the fractional of the fractional of the exercise of the selfer in cash, without interest and less any required withholding taxes, over the per-share exercise price of such option.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.